DOCSLIB.ORG

Health Care Opportunities Portfolio // Portfolio Selected By: Peroni Portfolio Advisors, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Health Care Opportunities Portfolio // Portfolio Selected By: Peroni Portfolio Advisors, Inc EQUITY - SECTOR / INDUSTRY FOCUS Series 2020-2, ADT 2019 Health Care Opportunities Portfolio // Portfolio Selected by: Peroni Portfolio Advisors, Inc. Morningstar Equity Style BoxTM Investment Objective & Strategy The Health Care Opportunities Portfolio, a unit investment trust (UIT), seeks to provide capital appreciation by investing in a portfolio of common stocks of companies involved in various areas of the health care sector including biotechnology, life sciences, medical equipment/technology, health care providers and pharmaceuticals. The portfolio was selected by Eugene E. Peroni, Jr. of Peroni Portfolio Advisors, Inc., the Portfolio Consultant, through the application of his proprietary method of technical analysis, the Peroni Method®, with consideration of investment opportunities under the health care theme. Ticketing Information CUSIP (Cash/Reinvest) 00780M743 / 750 Health Care Today Fee-Based CUSIP (Cash/Reinvest) 00780M768 / 776 MSWM Cash AHCP202 The United States Census Bureau projects a rapid increase in the elderly population over the next several decades and beyond. Baby boomers are the single largest generation in American history Essential Information and this generation may require massive amounts of health care in the near future. Globally, Unit price at inception (per unit) $10.000 people are living longer than they used to due to advances in health care technology, treatments Initial redemption price (per unit) $9.7750 and services. In this regard, the Health Care Opportunities Portfolio includes stocks in a number of Initial date of deposit 6/11/2020 industries involved in the many facets of health care that should be considered long term when Portfolio ending date 6/8/2022 investing in this diverse sector. Distribution frequency Semi-Annual, if any Number of Holdings 45 Historical 12-Month Distribution Rate of Trust Holdings* 0.33% *The distribution rate paid by the trust may be higher or lower than the amount shown above due to factors including, but not limited to, changes in the price of trust units, changes (including reductions) in distributions paid by issuers, changes in actual trust expenses and sales of securities in the portfolio. There is no guarantee that the issuers of the securities included in the trust will pay any distributions in the future. The Historical 12-Month Distribution Rate of Trust Holdings is calculated by taking the weighted average of the regular income distributions paid by the securities included in the trust’s portfolio over the 12 months preceding the trust’s date of deposit reduced to account for the effects of trust fees and expenses. The percentage shown is based on a $10 unit price. This historical rate is for illustrative purposes only and is not indicative of amounts that will actually be distributed by the trust. Sales Charges (Based on $10 unit price)+ As a % of $10 Amount per Standard Accounts unit price 100 units Initial sales fee 0.00% $0.00 Deferred sales fee 2.25% $22.50 Creation & Development fee 0.50% $5.00 Maximum sales fee 2.75% $27.50 As a % of $10 Amount per Fee-Based Accounts unit price 100 units Maximum sales fee 0.50% $5.00 +The initial sales fee is the difference between the total sales fee (maximum of 2.75% of the unit offering price) and the sum of the remaining deferred sales fee and the total creation and development fee. The deferred sales fee is fixed at $0.225 per unit and is paid in three monthly installments beginning December 20, 2020. The creation and development fee is fixed at $0.05 per unit and is paid at the end of the initial offering period (anticipated to be approximately three months). When the public offering price per unit is less than or equal to $10, you will not pay an initial sales fee. When the public offering price per unit price is greater than $10 per unit, you will pay an initial sales fee. The initial and deferred sales fees may not apply Page 1 of 4 to fee-based accounts. See the prospectus for more details about fee-based account eligibility requirements. Advisors Asset Management, Inc. (AAM) is a SEC registered investment advisor and member FINRA/SIPC. Health Care Opportunities Portfolio Series 2020-2, ADT 2019 Portfolio Holdings (as of date of deposit) Ticker Market Value Ticker Market Value Symbol Issue Name Per Share* Symbol Issue Name Per Share* Health Care (100%) Health Care (continued...) Health Care Equipment & Services (46.76%) Pharmaceuticals, Biotechnology (53.24%) ABMD ABIOMED, Inc. $250.85 ABBV AbbVie, Inc. $96.90 ABT Abbott Laboratories 92.16 AMGN Amgen, Inc. 227.12 CHE Chemed Corporation 448.70 ARNA Arena Pharmaceuticals, Inc. 64.60 COO The Cooper Companies, Inc. 298.63 AZN AstraZeneca PLC 53.64 DGX Quest Diagnostics, Inc. 114.31 BHVN Biohaven Pharmaceutical Holding Company Ltd. 66.67 DHR Danaher Corporation 172.69 BMRN BioMarin Pharmaceutical, Inc. 107.66 DVA DaVita, Inc. 82.90 BMY Bristol-Myers Squibb Company 60.16 DXCM DexCom, Inc. 385.17 CRL Charles River Laboratories International, Inc. 181.71 EW Edwards Lifesciences Corporation 73.28 ICLR ICON PLC 165.58 HUM Humana, Inc. 392.51 ILMN Illumina, Inc. 359.05 IDXX IDEXX Laboratories, Inc. 321.89 INCY Incyte Corporation 93.04 ISRG Intuitive Surgical, Inc. 585.38 JNJ Johnson & Johnson 147.80 LH Laboratory Corporation of America Holdings 175.10 LGND Ligand Pharmaceuticals, Inc. 117.58 MASI Masimo Corporation 225.69 LLY Eli Lilly and Company 151.00 MOH Molina Healthcare, Inc. 178.84 MRK Merck & Company, Inc. 81.77 QDEL Quidel Corporation 166.76 MTD Mettler-Toledo International, Inc. 812.61 RMD ResMed, Inc. 166.50 NBIX Neurocrine Biosciences, Inc. 118.34 STE STERIS PLC 159.64 REGN Regeneron Pharmaceuticals, Inc. 606.59 TFX Teleflex, Inc. 366.73 RGEN Repligen Corporation 120.01 UNH UnitedHealth Group, Inc. 305.75 SGEN Seattle Genetics, Inc. 156.70 WST West Pharmaceutical Services, Inc. 212.87 SRPT Sarepta Therapeutics, Inc. 159.83 TECH Bio-Techne Corporation 262.00 TMO Thermo Fisher Scientific, Inc. 352.80 VRTX Vertex Pharmaceuticals, Inc. 274.34 *As of 6/10/2020 and may vary thereafter. Sector/Industry Group Breakdown** Holdings Style Summary** Country of Organization** % of Portfolio % of Portfolio % of Portfolio Health Care 100.00% Large-Cap Growth 20.08% United States 91.16% Health Care Equipment & Services 46.76% Large-Cap Value 6.59% Ireland 4.41% Pharmaceuticals, Biotechnology 53.24% Large-Cap Blend 20.15% United Kingdom 2.23% Source: Global Industry Classification Standard (GICS) Mid-Cap Growth 37.68% British Virgin Islands 2.20% Mid-Cap Value 4.44% **As of 6/11/2020 and may vary thereafter. Breakdowns are Source: Bloomberg based on the sources shown and may differ from any Mid-Cap Blend 4.47% category definitions used in selecting the trust portfolio. Small-Cap Growth 6.59% Source: Morningstar Page 2 of 4 Intelligent Investments. Independent Ideas. Health Care Opportunities Portfolio Series 2020-2, ADT 2019 The Peroni Method® The Peroni Method® is a proprietary form of technical analysis used by Eugene E. Peroni, Jr. of Peroni Portfolio Advisors, Inc. which uses a bottom-up approach in selecting stocks for certain AAM sector unit investment trusts. The foundation of this methodology is the basic understanding that every stock has its own “fingerprint” in the market place. Mr. Peroni tracks hundreds of stocks on a daily basis, identifying leading stocks and sectors in the market by analyzing price movements, money flow trends, and relative strength characteristics. His studies include the examination of a stock’s price architecture using hand-drawn point and figure charts which have been part of the methodology for over half a century. This hands-on research approach may be an attractive investment alternative to traditional fundamental analysis in that it considers a stock’s individual technical merits along with economic, monetary and geopolitical factors. The Peroni Method® may uncover emerging trends that could correspond to future stock performance. It has endured volatile markets while providing investors with uncommon insights and unique investment opportunities. Key Points to Consider • The speed and scale of the R&D response to the COVID-19 outbreak is unprecedented in human history, with billions of dollars being spent and committed in pursuit of drugs, vaccines and diagnostics for the virus. The expert consensus is that enhanced treatments for COVID-19 will likely be available by the end of 2020; and only 12 to 18 months will likely be needed to bring a vaccine to market at sufficient scale for widespread immunization, compared with the typical five or more years.1 • Chronic diseases and conditions are on the rise worldwide. An ageing population and changes in societal behavior are contributing to a steady increase in common and costly long-term health problems. The middle class is growing; and with urbanization accelerating, people are adopting a more sedentary lifestyle. This is pushing obesity rates and cases of diseases such as diabetes upward. According to the World Health Organization, chronic disease prevalence is expected to rise 57% between 2017 and 2020, causing increased demand on healthcare systems worldwide.2 • Recent health care statistics show that it is one of the largest and the fastest-growing industries in the world.3 • Global health care spending could reach over $10 trillion by 2022. • U.S. health care expenditures are expected to reach $4.3 trillion by 2023. • The U.S. has the greatest health care spending, sitting at $10,224 per capita. • According to the National Health Expenditure Data, under current U.S. law, national health spending is projected to grow at an average rate of 5.5% per year for 2018-27 and estimated to reach nearly $6.0 trillion by 2027. U.S. healthcare spending is projected to grow 0.8 percentage points faster than Gross Domestic Product (GDP) per year over the 2018-27 period; as a result, the health share of GDP and is expected to rise from 17.9% in 2017 to 19.4% by 2027.
Load more

Recommended publications
  • Biomarin Pharmaceutical Inc
    BIOMARIN PHARMACEUTICAL INC FORM 10-K (Annual Report) Filed 03/02/15 for the Period Ending 12/31/14 Address 105 DIGITAL DRIVE NOVATO, CA 94949 Telephone 4155066700 CIK 0001048477 Symbol BMRN SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2015, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 68 -0397820 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 770 Lindaro Street San Rafael, California 94901 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (415) 506-6700 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $.001 par value The NASDAQ Global Select Market Securities registered under Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
    [Show full text]
  • Reducing Prescription Drug Costs in Colorado Cost Drivers and Strategies to Address Them
    2nd Edition Reducing Prescription Drug Costs in Colorado Cost Drivers and Strategies to Address Them January 2021 Contents Forward to Reducing Prescription Drug Costs in Colorado, 2nd Edition ........... 4 2020 Updates to This Report .................................................................. 4 Executive Summary ............................................................................ 6 Introduction and Purpose ...................................................................... 6 Cost Drivers ...................................................................................... 7 Prioritized Solutions ............................................................................ 8 Learning from Medicaid Policy ............................................................... 12 The Department Invites Your Collaborative Partnership .................................. 12 Industry Trends and Background Information ............................................. 13 Prescription Drug Cost, Utilization, and Trends ........................................... 13 The U.S. Pays the Highest Prices for Pharmaceutical Drugs in the World .............. 16 Many Coloradans Aren’t Taking Their Drugs Appropriately Because They Can’t Afford Them, Often Leading to Worse Health Outcomes That Are More Costly ....... 16 Major Drivers of Prescription Drug Prices .................................................. 18 Patent Protections .............................................................................. 18 Anti-Competitive Practices and Price Fixing
    [Show full text]
  • Amifampridine Phosphate (Firdapse®)
    AMIFAMPRIDINE PHOSPHATE (FIRDAPSEVR ) IS EFFECTIVE AND SAFE IN A PHASE 3 CLINICAL TRIAL IN LEMS SHIN J OH, MD,1 NATALYA SHCHERBAKOVA, MD,2 ANNA KOSTERA-PRUSZCZYK, MD, PhD,3 MOHAMMAD ALSHARABATI, MD,1 MAZEN DIMACHKIE, MD,4 JOSE MUNOZ BLANCO, MD,5 THOMAS BRANNAGAN, MD,6 DRAGANA LAVRNIC´ , MD, PhD,7 PERRY B SHIEH, MD, PhD,8 CHRISTOPHE VIAL, MD,9 ANDREAS MEISEL, MD,10 SAMUEL KOMOLY, MD, PhD, DSc,11 BENEDIKT SCHOSER, MD,12 KUMARASWAMY SIVAKUMAR, MD,13 YUEN SO, MD, PhD,14 and LEMS STUDY GROUP 1 Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA 2 Russian Academy of Medical Sciences, Scientific Center of Neurology, Moscow, Russia 3 Department of Neurology, Medical University of Warsaw, Poland 4 University of Kansas Medical Center, Kansas City, Kansas, USA 5 Gregorio Maranon Hospital, Madrid, Spain 6 Columbia University Medical Center, New York, New York, USA 7 Clinical Center of Serbia, Clinic of Neurology, Belgrade, Serbia 8 Department of Neurology, University of California, Los Angeles, California, USA 9 Hospital of Lyon, ENMG Service and Neuromuscular Pathology Hospital, Lyon, France 10 Charite Universitatsmedizin Berlin-NeuroCure Clinical Research Center, Berlin, Germany 11 University of Pecs, Department of Neurology, Pecs, Hungary 12 Ludwig-Maximilians-University Munich Friedrich-Baur-Institute, Munich, Germany 13 Neuromuscular Research Center, Phoenix, Arizona, USA [email protected] 14 Stanford University, Stanford, California, USA Accepted 4 February 2016 ABSTRACT: Objective: We evaluated the efficacy and safety ated; the most common adverse events were oral and digital of amifampridine phosphate (FirdapseVR ) for symptomatic treat- paresthesias, nausea, and headache. Conclusions: This study ment in Lambert-Eaton myasthenic syndrome (LEMS).
    [Show full text]
  • List of Section 13F Securities, First Quarter, 2009
    List of Section 13F Securities 1st Quarter FY 2009 Copyright (c) 2009 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2009, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2009. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by [ Section 13(f)(1) and Rule 13f-1] thereunder.
    [Show full text]
  • 2019 Or ☐ TRANSITION REPORT PURSUANT to SECTION 13 OR 15(D) of the SECURITIES EXCHANGE ACT of 1934
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________ Form 10-K ____________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 ____________ BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) ____________ Delaware 68-0397820 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 770 Lindaro Street San Rafael California 94901 (Address of principal executive offices) (Zip Code) (415) 506-6700 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.001 BMRN The Nasdaq Global Select Market Securities registered under Section 12(g) of the Act: None ____________ Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • To Download the Full Report, Click Here
    STRENGTHENING BIOPHARMACEUTICAL Ohio BOLD:INNOVATION: A Blueprint forTHE Accelerating GROWING ROLE OF the InnovationCORPORATE Economy VENTURE CAPITAL Performed For: Ohio Chamber of Commerce Research Foundation OCTOBER 2018 Performed By: TEConomy Partners, LLC JULY 2018 Prepared for: Prepared by: TEConomy Partners, LLC (TEConomy) endeavors at all times to produce work of the highest quality, consistent with our contract commitments. However, because of the research and/or experimental nature of this work, the client under- takes the sole responsibility for the consequence of any use or misuse of, or inability to use, any information or result obtained from TEConomy, and TEConomy, its partners, or employees have no legal liability for the accuracy, adequa- cy, or efficacy thereof. TABLE OF CONTENTS Executive Summary i Introduction: Corporate Venture Capital Comes of Age 1 The Rise and Transformation of Corporate Venture Capital ...............................1 Innovation-based Biopharmaceutical Companies Are Leaders in CVC Investment.................................................................................4 Setting the Context: Growing PhRMA-member CVC activity comes at a time of unprecedented opportunity but rising challenges for medical innovation .................................................................................................6 Key Trends and Contributions of CVC Activity by Biopharmaceutical Companies 9 Biopharmaceutical CVCs are now a significant share of overall biopharmaceutical investment .............................................................10
    [Show full text]
  • Annual Report 2
    Draft as of December 20. PDF version for illustrative purposes, report will be published online. ANNUAL REPORT 2 Key Figures for 2019 MERCK GROUP Key figures Change € million 2019 2018 € million % Net sales 16,152 14,836 1,315 8.9% Operating result (EBIT)1 2,120 1,727 393 22.8% Margin (% of net sales)1 13.1% 11.6% EBITDA1 4,066 3,528 539 15.3% Margin (% of net sales)1 25.2% 23.8% EBITDA pre1 4,385 3,800 585 15.4% Margin (% of net sales)1 27.1% 25.6% Profit after tax 1,324 3,396 -2,072 -61.0% Earnings per share (in €) 3.04 7.76 -4.72 -60.8% Earnings per share pre (€)1 5.56 5.10 0.46 9.0% Business free cash flow1 2,732 2,508 224 8.9% 1Not defined by International Financial Reporting Standards (IFRSs). MERCK GROUP MERCK GROUP Net sales EBITDA pre1 € million € million 1 Not defined y International Financial Reporting Standards (IFRSs). Owing to the altered expectations in terms of the impact of the Covid-19 pandemic, some chapters of this Annual Report were updated on May 12, 2020. The respective text passages are marked in magenta. Table of Contents Annual Report To Our Shareholders Corporate Governance 5 Letter from Stefan Oschmann 136 Capital Structure and Corporate Bodies of Merck KGaA 8 The Executive Board 137 Statement on Corporate Governance including Compensation Report 9 Merck Shares 167 Report of the Supervisory Board 170 Objectives of the Supervisory Board with respect to Its Composition and Profile of Skills and Expertise Combined Consolidated Management Report Financial Statements 12 Fundamental Information about the 174 Consolidated
    [Show full text]
  • 2019 Annual Report
    2019 ANNUAL REPORT Dear Shareholders, I am pleased to report that 2019 was a very positive and transformational year for Catalyst and, most importantly, for the patients that we seek to help. The year was purpose-driven, as we transformed to a fully integrated commercial-stage biopharmaceutical company with the successful launch of Firdapse® for adult patients suffering from Lambert-Eaton Myasthenic Syndrome (LEMS). We are gratified with the positive response that we have received from the LEMS community of patients and healthcare providers since our launch of Firdapse® in January 2019. We believe that it was extremely important to go through the rigors required to get Firdapse® approved by the FDA, so that all adult LEMS patients, and not just a select few who participated in an early access program, would have affordable access to an FDA approved therapy to treat their rare disease. Of all that we accomplished in 2019 and during the first half of 2020, I am proud that because of the efforts of the Catalyst team, Firdapse® has become the market leader and standard of care for the treatment of adult LEMS patients. I am most excited by the growth and progress that our company has made across all functional areas of our business, including the financial results that we reported for our first year as a commercial company. When we launched Firdapse® (amifampridine) 10 mg tablets in the U.S. for adult LEMS patients, we identified key objectives for the year based upon-patient enrollments in Catalyst Pathways, physician adoption rates for Firdapse®, and high patient satisfaction ratings.
    [Show full text]
  • Investor Relations : Biomarin
    BIOMARIN PHARMACEUTICAL INC FORM 10-K (Annual Report) Filed 02/26/13 for the Period Ending 12/31/12 Address 105 DIGITAL DRIVE NOVATO, CA 94949 Telephone 4155066700 CIK 0001048477 Symbol BMRN SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2013, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 68 -0397820 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 770 Lindaro Street San Rafael, California 94901 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (415) 506-6700 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $.001 par value The NASDAQ Global Select Market Securities registered under Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
    [Show full text]
  • Investor Relations : Biomarin
    BIOMARIN PHARMACEUTICAL INC FORM 10-K (Annual Report) Filed 02/29/16 for the Period Ending 12/31/15 Address 105 DIGITAL DRIVE NOVATO, CA 94949 Telephone 4155066700 CIK 0001048477 Symbol BMRN SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2016, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. ff UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 68-0397820 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 770 Lindaro Street San Rafael, California 94901 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (415) 506-6700 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $.001 par value The NASDAQ Global Select Market Securities registered under Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No ¨ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
    [Show full text]
  • ANNUAL REPORT 2018 … Is at the Heart of Every- Thing We Do
    Science ANNUAL REPORT 2018 … is at the heart of every- thing we do. € 2.2 BILLION invested in research and development in 2018. Around 52,000 hearts at Merck beat for science. Employees in 66 countries share a passion for pushing boundaries and making new discoveries. Since 1668, the name Merck has stood for the positive power of science. Online You can find out what else makes our research hearts beat faster at www.merckgroup.com/en/ annualreport/2018 “ We believe that scientific exploration and responsible entrepreneurship make techno- logical advantages possible that benefit us all.” STEFAN OSCHMANN Chairman of the Executive Board and CEO Key Figures for 2018 MERCK GROUP Key figures 1 Change € million 2018 2017 € million in % Net sales 14,836 14,517 319 2.2% Operating result (EBIT)2 1,727 2,423 – 696 – 28.7% Margin (% of net sales)2 11.6% 16.7% EBITDA2 3,528 4,164 – 636 – 15.3% Margin (% of net sales)2 23.8% 28.7% EBITDA pre2 3,800 4,246 – 446 – 10.5% Margin (% of net sales)2 25.6% 29.3% Profit after tax 3,396 2,615 781 29.9% Earnings per share (€) 7.76 5.99 1.77 29.5% Earnings per share pre (€)2 5.10 5.92 – 0.82 – 13.9% Business free cash flow2 2,508 3,193 – 685 – 21.4% 1 Fiscal 2017 has been adjusted, see Note (49) “Effects from new accounting standards and other presentation and measurement changes” in the Notes to the Consolidated Financial Statements. 2 Not defined by International Financial Reporting Standard IFRS( s).
    [Show full text]